CLDX Celldex Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLDX

Price (delayed)

$30.57

Market cap

$1.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.53

Enterprise value

$1.39B

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which ...

Highlights
The debt has increased by 38% YoY but it has decreased by 9% QoQ
The company's gross profit rose by 34% QoQ but it fell by 24% YoY
Celldex Therapeutics's net income has plunged by 54% YoY and by 6% from the previous quarter
CLDX's EPS is down by 48% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.celldex.com
Peers: SGEN AGEN NWBO EBS

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
47.25M
Market cap
$1.44B
Enterprise value
$1.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.77
Price to sales (P/S)
458.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
442.55
Earnings
Revenue
$3.15M
EBIT
-$118.64M
EBITDA
-$115.83M
Free cash flow
-$109.54M
Per share
EPS
-$2.53
Free cash flow per share
-$2.32
Book value per share
$6.41
Revenue per share
$0.07
TBVPS
$6.3
Balance sheet
Total assets
$324.52M
Total liabilities
$21.78M
Debt
$3.65M
Equity
$302.74M
Working capital
$274.38M
Liquidity
Debt to equity
0.01
Current ratio
19.03
Quick ratio
18.38
Net debt/EBITDA
0.44
Margins
EBITDA margin
-3,677%
Gross margin
100%
Net margin
-3,766.2%
Operating margin
-4,151.6%
Efficiency
Return on assets
-32.7%
Return on equity
-35.4%
Return on invested capital
-41.4%
Return on capital employed
-38.4%
Return on sales
-3,766.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
0.66%
1 week
-7.05%
1 month
-5.44%
1 year
14.92%
YTD
-31.41%
QTD
-15.04%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$3.15M
Gross profit
$3.15M
Operating income
-$130.77M
Net income
-$118.64M
Gross margin
100%
Net margin
-3,766.2%
CLDX's operating margin has dropped by 114% year-on-year but it is up by 20% since the previous quarter
The net margin has shrunk by 102% YoY but it has increased by 21% QoQ
Celldex Therapeutics's operating income has shrunk by 63% YoY and by 7% QoQ
Celldex Therapeutics's net income has plunged by 54% YoY and by 6% from the previous quarter

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
4.77
P/S
458.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
442.55
CLDX's EPS is down by 48% YoY and by 5% from the previous quarter
The P/B is 70% higher than the 5-year quarterly average of 2.8
Celldex Therapeutics's equity has decreased by 24% YoY and by 7% from the previous quarter
CLDX's price to sales (P/S) is 57% higher than its 5-year quarterly average of 292.3 but 56% lower than its last 4 quarters average of 1044.8
Celldex Therapeutics's revenue has increased by 34% from the previous quarter but it has decreased by 24% YoY

Efficiency

How efficient is Celldex Therapeutics business performance
CLDX's ROS has plunged by 102% YoY but it is up by 21% from the previous quarter
The ROE has plunged by 65% YoY and by 13% from the previous quarter
The ROA has shrunk by 63% YoY and by 13% QoQ
Celldex Therapeutics's ROIC has plunged by 60% YoY and by 17% from the previous quarter

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
CLDX's quick ratio is down by 30% year-on-year but it is up by 12% since the previous quarter
The current ratio has decreased by 29% YoY but it has increased by 11% from the previous quarter
The debt is 99% lower than the equity
The debt has increased by 38% YoY but it has decreased by 9% QoQ
Celldex Therapeutics's equity has decreased by 24% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.